MARLBOROUGH, MA--(Marketwired - Jan 20, 2016) - Averica Discovery, an analytical development contract research organization (CRO) with specialized expertise in small molecule analysis and purification, today announced the appointment of Cynthia Berger, Ph.D., to the newly-created position of Vice President of Operations.
In her new role, Dr. Berger will directly report to CEO Jeff Kiplinger and is expected to contribute broadly to Averica's growth and development.
"We are excited to welcome Cindy, who will provide significant insight and guidance to our growth as an analytical development company," said Jeff Kiplinger. "Cindy will be exploring new ways to expand our capabilities and enhance the value we bring to clients. She will also oversee the standardization of many of our processes as we move toward ISO 17025 certification and add GMP analytical capabilities. Her significant experience and strong understanding of the analytical services market, coupled with her strong operations, financial, and business background, make her an essential asset to the future of Averica."
Prior to joining Averica Discovery, Dr. Berger served as project manager at PCI Synthesis, a contract manufacturing organization (CMO), where she managed multimillion dollar projects manufacturing active pharmaceutical ingredients. Previously, she was Vice President and a co-founder of Pion Inc., an instrumentation company and CRO, where she developed and grew markets for instrumentation, established a contract research laboratory, and led the successful sale of Pion to a private investment group. Dr. Berger was a key contributor to the development of Pion's instruments and intellectual property. Dr. Berger earned her Ph.D. in Chemistry from Penn State University.
About Averica Discovery
Founded in 2007, Averica Discovery is a Massachusetts-based analytical development contract research organization (CRO) with specialized expertise in small molecule analysis and purification. The company supports chemistry teams by providing material and information required to transition programs from drug discovery to development. With extensive experience in pharmaceutical R&D, it currently offers a variety of chromatography-based services, including method development and qualification, impurity isolation and identification, scalable small molecule purification, and custom assay development.